Loading...

HBIO HARVARD BIOSCIENCE INC Management Changes 8-K Filing

HRVR

HB

HARVARD BIOSCIENCE INC

(HBIO)

2025 8-K

Corporate Update

Financial Results Announced

Management Changes

Stock Split Approved

Financial Results Update

Operational Changes

By-law Amendment

Investor Update

Loan Agreement Details

Credit Agreement Update

Financial Results Announced

Nasdaq Compliance Update

Board Appointment

Management Change

Notice of Delisting

Financial Statements

Director Departure

Delisting Notice

Financial Results

Credit Agreement Amendment

Financial Results

Annual Meeting of Stockholders

Credit Agreement Amendment

Compensation Committee Appr...

Financial Results Announcement

Financial Condition and Res...

Appointment of CFO

Annual Meeting of Stockholders

Compensation Committee Appr...

Financial Results Announcement

Resignation of CFO

External Links:

On May 30, 2025, Thomas Loewald resigned from Harvard Bioscience’s board without any disagreements, and on June 2, 2025, the company approved an increase of 3,923,000 shares for its 2021 Incentive Plan, among other board changes such as appointing John D. Duke and Katherine Eade. The resignation and incentive plan modifications are significant for company governance and shareholder equity.

AI Assistant

HARVARD BIOSCIENCE INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.